Search Results

You are looking at 11 - 20 of 40 items for :

  • "accelerated phase" x
  • Refine by Access: All x
Clear All
Full access

Chronic Myelogenous Leukemia

Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler, and Furhan Yunus

expression profiling has shown a close correlation of gene expressions between the accelerated and blast phase. Most of the genetic changes in progression occur during the transition from chronic to accelerated phase. 3 Untreated chronic phase CML (CP

Full access

10 Years of Progress in Chronic Myelogenous Leukemia

Elias Jabbour, Michael S. Mathisen, and Susan O’Brien

from progression to accelerated phase or blast crisis at 12 months (99% vs. 93%; P < .001). Further highlighting the challenge of using IFN-α was the high crossover rate to imatinib due to intolerance. The responses to imatinib were also durable, as

Full access

How to Monitor Patients with Chronic Myelogenous Leukemia

Michael E O'Dwyer

– 1538 . 20 O'Dwyer ME Mauro MJ Kurilik G . The impact of clonal evolution on response to Gleevec (imatinib mesylate) in accelerated phase CML . Blood 2002 ; 100 : 1628 – 1633 . 21 Seong DC Kantarjian HM Ro JY . Hypermetaphase

Full access

New Agents in the Treatment of Chronic Myelogenous Leukemia

Javier Pinilla-Ibarz and Alfonso Quintás-Cardama

. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia . Blood 2008 ; 111 : 1834 – 1839 . 40 le Coutre PD

Full access

Chronic Myelogenous Leukemia

Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz, and Meir Wetzler

Guilhot F Apperley J Kim DW . Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase . Blood 2007 ; 109 : 4143 – 4150 . 27 Apperley

Full access

Pharmacotherapy for Chronic Myelogenous Leukemia: A Case-Based Approach

Stephen Harnicar

showed that 100 mg once daily was able to maintain efficacy while reducing toxicity compared with 70 mg twice daily. Another phase III trial evaluating once-daily dosing of dasatinib in accelerated phase CML 43 showed an improved toxicity profile with

Full access

Resistance to Imatinib: Mechanisms and Management

Michael Deininger

Talpaz M Silver RT Druker BJ . Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study . Blood 2002 ; 99 : 1928 – 1937 . 3 Sawyers CL Hochhaus A

Full access

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

Jerald P. Radich and Vivian Oehler

: American Society of Hematology , 2002 : 111 – 135 . 6. Talpaz M Silver RT Druker BJ . Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

Full access

A Quick REMS Update and a Clinical Focus

Edward C. Li

Journal of Medicine challenge the notion of imatinib for first-line therapy for CML. 2 , 3 These 2 studies found a superior effect in terms of complete cytogenetic remission, time to remission, and rate of progression to accelerated phase or blast crisis

Full access

Where Exactly Does Ponatinib Fit in Chronic Myelogenous Leukemia?

Ellin Berman

patients with this mutation, Nicolini et al 15 reported that 17% experienced progression to accelerated phase and 25% to blastic phase, with a median overall survival after mutation detection of 22.4 months. Ponatinib was specifically designed to